

Magdalena Kotańska

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4285066/publications.pdf>

Version: 2024-02-01

73
papers

937
citations

471061
17
h-index

580395
25
g-index

75
all docs

75
docs citations

75
times ranked

1323
citing authors

#	ARTICLE	IF	CITATIONS
1	Guanabenzâ€”an old drug with a potential to decrease obesity. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2022, 395, 963-974.	1.4	2
2	Hydroalcoholic Leaf Extract of <i>Isatis tinctoria</i> L. via Antioxidative and Anti-Inflammatory Effects Reduces Stress-Induced Behavioral and Cellular Disorders in Mice. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-18.	1.9	5
3	KSK-74: Dual Histamine H3 and Sigma-2 Receptor Ligand with Anti-Obesity Potential. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7011.	1.8	3
4	Structural modifications in the distal, regulatory region of histamine H3 receptor antagonists leading to the identification of a potent anti-obesity agent. <i>European Journal of Medicinal Chemistry</i> , 2021, 213, 113041.	2.6	10
5	Effects of GPR18 Ligands on Body Weight and Metabolic Parameters in a Female Rat Model of Excessive Eating. <i>Pharmaceuticals</i> , 2021, 14, 270.	1.7	7
6	PSB 603 â€” a known selective adenosine A2B receptor antagonist â€” has anti-inflammatory activity in mice. <i>Biomedicine and Pharmacotherapy</i> , 2021, 135, 111164.	2.5	21
7	Discovery of Potential, Dual-Active Histamine H3 Receptor Ligands with Combined Antioxidant Properties. <i>Molecules</i> , 2021, 26, 2300.	1.7	3
8	MH-76, a Novel Non-Quinazoline $\hat{\pm}$ 1-Adrenoceptor Antagonist, but Not Prazosin Reduces Inflammation and Improves Insulin Signaling in Adipose Tissue of Fructose-Fed Rats. <i>Pharmaceuticals</i> , 2021, 14, 477.	1.7	6
9	Design, Sustainable Synthesis and Biological Evaluation of a Novel Dual $\hat{\pm}$ 2A/5-HT7 Receptor Antagonist with Antidepressant-Like Properties. <i>Molecules</i> , 2021, 26, 3828.	1.7	8
10	Multifunctional Arylsulfone and Arylsulfonamide-Based Ligands with Prominent Mood-Modulating Activity and Benign Safety Profile, Targeting Neuropsychiatric Symptoms of Dementia. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 12603-12629.	2.9	5
11	The GPR18 Agonist PSB-KD-107 Exerts Endothelium-Dependent Vasorelaxant Effects. <i>Pharmaceuticals</i> , 2021, 14, 799.	1.7	7
12	Influence of betahistidine repeated administration on a weight gain and selected metabolic parameters in the model of excessive eating in rats. <i>Biomedicine and Pharmacotherapy</i> , 2021, 141, 111892.	2.5	3
13	Metabolic benefits of novel histamine H3 receptor ligands in the model of excessive eating: The importance of intrinsic activity and pharmacokinetic properties. <i>Biomedicine and Pharmacotherapy</i> , 2021, 142, 111952.	2.5	6
14	Histamine H3 Receptor Ligandsâ€”KSK-59 and KSK-73â€”Reduce Body Weight Gain in a Rat Model of Excessive Eating. <i>Pharmaceuticals</i> , 2021, 14, 1080.	1.7	3
15	Antinociceptive, antiedematous, and antiallodynic activity of 1H-pyrrolo[3,4-c]pyridine-1,3(2H)-dione derivatives in experimental models of pain. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2020, 393, 813-827.	1.4	8
16	Antidepressant-like activity and safety profile evaluation of 1H-imidazo[2,1-f]purine-2,4(3H,8H)-dione derivatives as 5-HT1A receptor partial agonists. <i>PLoS ONE</i> , 2020, 15, e0237196.	1.1	7
17	KD-64â€”A new selective A2A adenosine receptor antagonist has anti-inflammatory activity but contrary to the non-selective antagonistâ€”Caffeine does not reduce diet-induced obesity in mice. <i>PLoS ONE</i> , 2020, 15, e0229806.	1.1	10
18	Pitolisant protects mice chronically treated with corticosterone from some behavioral but not metabolic changes in corticosterone-induced depression model. <i>Pharmacology Biochemistry and Behavior</i> , 2020, 196, 172974.	1.3	5

#	ARTICLE	IF	CITATIONS
19	Title is missing!. , 2020, 15, e0229806.		0
20	Title is missing!. , 2020, 15, e0229806.		0
21	Title is missing!. , 2020, 15, e0229806.		0
22	Title is missing!. , 2020, 15, e0229806.		0
23	The 1,3,5-Triazine Derivatives as Innovative Chemical Family of 5-HT ₆ Serotonin Receptor Agents with Therapeutic Perspectives for Cognitive Impairment. International Journal of Molecular Sciences, 2019, 20, 3420.	1.8	43
24	KSK19 – Novel histamine H ₃ receptor ligand reduces body weight in diet induced obese mice. Biochemical Pharmacology, 2019, 168, 193-203.	2.0	15
25	Structural modifications and in vitro pharmacological evaluation of 4-pyridyl-piperazine derivatives as an active and selective histamine H ₃ receptor ligands. Bioorganic Chemistry, 2019, 91, 103071.	2.0	14
26	Beneficial effects of non-quinazoline \pm 1-adrenolytics on hypertension and altered metabolism in fructose-fed rats. A comparison with prazosin. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 751-760.	1.1	8
27	Anti-Alzheimer's multitarget-directed ligands with serotonin 5-HT ₆ antagonist, butyrylcholinesterase inhibitory, and antioxidant activity. Archiv Der Pharmazie, 2019, 352, e1900041.	2.1	16
28	Reversal of cardiac, vascular, and renal dysfunction by non-quinazoline \pm 1-adrenolytics in DOCA-salt hypertensive rats: a comparison with prazosin, a quinazoline-based \pm 1-adrenoceptor antagonist. Hypertension Research, 2019, 42, 1125-1141.	1.5	11
29	Are the Hydantoin-1,3,5-triazine 5-HT ₆ R Ligands a Hope to a Find New Procognitive and Anti-Obesity Drug? Considerations Based on Primary In Vivo Assays and ADME-Tox Profile In Vitro. Molecules, 2019, 24, 4472.	1.7	18
30	Can Lipoic Acid Attenuate Cardiovascular Disturbances Induced by Ethanol and Disulfiram Administration Separately or Jointly in Rats?. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-10.	1.9	4
31	Is the mechanism of nitroglycerin tolerance associated with aldehyde dehydrogenase activity? A contribution to the ongoing discussion. Acta Biochimica Polonica, 2019, 66, 627-632.	0.3	3
32	Single Administration of HBK-15 – a Triple 5-HT _{1A} , 5-HT ₇ , and 5-HT ₃ Receptor Antagonist – Reverses Depressive-Like Behaviors in Mouse Model of Depression Induced by Corticosterone. Molecular Neurobiology, 2018, 55, 3931-3945.	1.9	20
33	Synthesis and biological evaluation of <i>N</i> -aryl piperazine derivatives of 4,4-dimethylisoquinoline-1,3(2 <i>H</i>),4 <i>H</i> -dione as potential antiplatelet agents. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, 536-545.	2.5	13
34	Synthesis and biological activity of novel tert-butyl and tert-pentylphenoxyalkyl piperazine derivatives as histamine H ₃ R ligands. European Journal of Medicinal Chemistry, 2018, 152, 223-234.	2.6	24
35	Idalopirdine, a selective 5-HT ₆ receptor antagonist, reduces food intake and body weight in a model of excessive eating. Metabolic Brain Disease, 2018, 33, 733-740.	1.4	30
36	Involvement of the NO/sGC/cGMP/K ⁺ channels pathway in vascular relaxation evoked by two non-quinazoline \pm 1-adrenoceptor antagonists. Biomedicine and Pharmacotherapy, 2018, 103, 157-166.	2.5	7

#	ARTICLE	IF	CITATIONS
37	Metabolic benefits of 1-(3-(4-(o-tolyl)piperazin-1-yl)propyl)pyrrolidin-2-one: a non-selective $\hat{1}\pm$ -adrenoceptor antagonist. <i>Journal of Endocrinological Investigation</i> , 2018, 41, 609-619.	1.8	7
38	Novel and effective synthesis protocol of AgNPs functionalized using L-cysteine as a potential drug carrier. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2018, 391, 123-130.	1.4	19
39	Anti-aggregation effect of aroxyalkyl derivatives of 2-methoxyphenylpiperazine is due to their 5-HT _{2A} and $\hat{1}\pm$ -adrenoceptor antagonistic properties. A comparison with ketanserin, sarpogrelate, prazosin, yohimbine and ARC239. <i>European Journal of Pharmacology</i> , 2018, 818, 263-270.	1.7	8
40	Optimization and preclinical evaluation of novel histamine H ₃ receptor ligands: Acetyl and propionyl phenoxyalkyl piperazine derivatives. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 6056-6066.	1.4	12
41	Computer-Aided Studies for Novel Arylhydantoin 1,3,5-Triazine Derivatives as 5-HT ₆ Serotonin Receptor Ligands with Antidepressive-Like, Anxiolytic and Antiobesity Action In Vivo. <i>Molecules</i> , 2018, 23, 2529.	1.7	18
42	Synthesis and Pharmacological Evaluation of Novel Silodosin-Based Arylsulfonamide Derivatives as $\hat{1}\pm$ A/ $\hat{1}\pm$ D-Adrenergic Receptor Antagonist with Potential Uroselective Profile. <i>Molecules</i> , 2018, 23, 2175.	1.7	2
43	The histamine H ₃ receptor inverse agonist pitolisant reduces body weight in obese mice. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2018, 391, 875-881.	1.4	18
44	Yohimbine improves lipid and carbohydrate profiles without reduction in body weight in obese leptin-deficient ob/ob mice. <i>Journal of Pre-Clinical and Clinical Research</i> , 2018, 12, 67-71.	0.2	2
45	HBK-15 protects mice from stress-induced behavioral disturbances and changes in corticosterone, BDNF, and NGF levels. <i>Behavioural Brain Research</i> , 2017, 333, 54-66.	1.2	18
46	Contribution of the nitric oxide donor molsidomine and the antiparkinsonian drug L-DOPA to the modulation of the blood pressure in unilaterally 6-OHDA-lesioned rats. <i>Pharmacological Reports</i> , 2017, 69, 29-35.	1.5	2
47	Metabolic and Cardiovascular Benefits and Risks of EMD386088 as a 5-HT ₆ Receptor Partial Agonist and Dopamine Transporter Inhibitor. <i>Frontiers in Neuroscience</i> , 2017, 11, 50.	1.4	16
48	The effect of NaCl on the level of reduced sulfur compounds in rat liver. Implications for blood pressure increase. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2017, 71, 0-0.	0.1	1
49	Chemically Homogenous Compounds with Antagonistic Properties at All $\hat{1}\pm$ -Adrenoceptor Subtypes but not $\hat{1}\pm$ -Adrenoceptor Attenuate Adrenaline-Induced Arrhythmia in Rats. <i>Frontiers in Pharmacology</i> , 2016, 7, 229.	1.6	17
50	H ₃ histamine receptor antagonist pitolisant reverses some subchronic disturbances induced by olanzapine in mice. <i>Metabolic Brain Disease</i> , 2016, 31, 1023-1029.	1.4	24
51	Arylsulfonamide derivatives of (aryloxy)ethyl pyrrolidines and piperidines as $\hat{1}\pm$ -adrenergic receptor antagonist with uro-selective activity. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 5582-5591.	1.4	3
52	Evaluation of antidepressant-like and anxiolytic-like activity of purinedione-derivatives with affinity for adenosine A _{2A} receptors in mice. <i>Pharmacological Reports</i> , 2016, 68, 1285-1292.	1.5	10
53	Synthesis and Pharmacological Activity of a New Series of 1-((1 <i>H</i> -indol-4-yl)oxy)-3-(2-(2-methoxyphenoxy)ethylamino)propan-2-ol Analogs. <i>Archiv Der Pharmazie</i> , 2016, 349, 211-223.	1.4	10
54	Antiarrhythmic activity in occlusion-reperfusion model of 1-((1 <i>H</i> -indol-4-yl)oxy)-3-(2-(2-methoxyphenoxy)ethyl)amino} propan-2-ol and its enantiomers. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2016, 43, 81-87.	1.4	10

#	ARTICLE	IF	CITATIONS
55	Pyrrolidin-2-one derivatives may reduce body weight in rats with diet-induced obesity. <i>European Journal of Pharmacology</i> , 2016, 776, 146-155.	1.7	15
56	Antidepressant-like activity of aroxyalkyl derivatives of 2-methoxyphenylpiperazine and evidence for the involvement of serotonin receptor subtypes in their mechanism of action. <i>Pharmacology Biochemistry and Behavior</i> , 2016, 141, 28-41.	1.3	17
57	HBK-14 and HBK-15 Do Not Influence Blood Pressure, Lipid Profile, Glucose Level, or Liver Enzymes Activity after Chronic Treatment in Rats. <i>PLoS ONE</i> , 2016, 11, e0165495.	1.1	8
58	Antiarrhythmic and α -Adrenoceptor Antagonistic Properties of Novel Arylpiperazine Derivatives of Pyrrolidin-2-one. <i>Archiv Der Pharmazie</i> , 2015, 348, 861-867.	2.1	3
59	A Comparison of the Anorectic Effect and Safety of the Alpha2-Adrenoceptor Ligands Guanfacine and Yohimbine in Rats with Diet-Induced Obesity. <i>PLoS ONE</i> , 2015, 10, e0141327.	1.1	28
60	The influence of the route of administration of gold nanoparticles on their tissue distribution and basic biochemical parameters: In vivo studies. <i>Pharmacological Reports</i> , 2015, 67, 405-409.	1.5	77
61	Antinociceptive, anti-inflammatory and smooth muscle relaxant activities of the pyrrolo[3,4-d]pyridazinone derivatives: Possible mechanisms of action. <i>Pharmacology Biochemistry and Behavior</i> , 2015, 133, 99-110.	1.3	35
62	Antiarrhythmic activity of new 2-methoxyphenylpiperazine xanthone derivatives after ischemia/reperfusion in rats. <i>Pharmacological Reports</i> , 2015, 67, 1163-1167.	1.5	9
63	α -Adrenoceptor antagonistic and hypotensive properties of novel arylpiperazine derivatives of pyrrolidin-2-one. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 2104-2111.	1.4	11
64	Idalopirdine – a small molecule antagonist of 5-HT ₆ with therapeutic potential against obesity. <i>Metabolic Brain Disease</i> , 2015, 30, 1487-1494.	1.4	35
65	Hypotensive effect of alpha-lipoic acid after a single administration in rats. <i>Anatolian Journal of Cardiology</i> , 2015, 16, 306-9.	0.5	9
66	Alpha lipoic acid protects the heart against myocardial post ischemia reperfusion arrhythmias via KATP channel activation in isolated rat hearts. <i>Pharmacological Reports</i> , 2014, 66, 499-504.	1.5	38
67	Evaluation of anticonvulsant activity of novel pyrrolidin-2-one derivatives. <i>Pharmacological Reports</i> , 2014, 66, 708-711.	1.5	9
68	Tissue distribution of gold nanoparticles after single intravenous administration in mice. <i>Pharmacological Reports</i> , 2013, 65, 1033-1038.	1.5	18
69	Are anti-inflammatory properties of lipoic acid associated with the formation of hydrogen sulfide?. <i>Pharmacological Reports</i> , 2013, 65, 1018-1024.	1.5	20
70	In Vivo Anti-inflammatory Activity of Lipoic Acid Derivatives in Mice. <i>Postepy Higieny I Medycyny Doswiadczonej</i> , 2013, 67, 331-338.	0.1	15
71	Effects of Different Garlic-derived Allyl Sulfides on Peroxidative Processes and Anaerobic Sulfur Metabolism in Mouse Liver. <i>Phytotherapy Research</i> , 2012, 26, 425-431.	2.8	26
72	The effect of nitroglycerin tolerance on oxidative stress and anaerobic sulfur metabolism in rat tissues. <i>Fundamental and Clinical Pharmacology</i> , 2010, 24, 47-53.	1.0	5

#	ARTICLE	IF	CITATIONS
73	The role of lipoic acid in prevention of nitroglycerin tolerance. European Journal of Pharmacology, 2008, 591, 203-210.	1.7	27